Developer docs
API playgroundTry for free, no card

Search company profiles

Ingenium Therapeutics

Full company profile

uuid0002psl

Namestring
Ingenium Therapeutics
Legal namestring
Ingenium Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Ingenium Therapeutics, Inc. is a South Korea-based clinical-stage biotechnology company founded in November 2020 as a spin-off of the Korea Research Institute of Biosciences and Biotechnology (KRIBB), commercializing NK cell-based anti-cancer immunotherapy built on roughly two decades of KRIBB research. Its core asset is Gengleucel (formerly IGNK001), an allogeneic Memory NK cell therapy manufactured from healthy donor PBMCs via a proprietary feeder-cell-free cytokine differentiation process, with enhanced activating receptors (CD94, NKG2D, NKp30, NKp44, NKp46), up to 100-fold higher IFN-gamma secretion, and 24-month freeze/thaw stability enabling off-the-shelf use. The lead indication is relapsed/refractory acute myeloid leukemia (R/R AML), where four investigator-initiated trials have enrolled 140+ patients and reported a 37.5% complete remission rate in evaluable patients; the asset received FDA Orphan Drug Designation in 2024 and positive pre-IND feedback enabling direct US Phase 2 entry. The pipeline is expanding into solid tumors via the IG301 in vivo CAR-NK platform (5th-generation mRNA CAR with non-LNP delivery, co-developed with Yale University), IG101 and IG201 ROR1-targeted Target Immune Stimulators (TIS), the TN13 peptide-based p38 inhibitor that restores NK function in TGF-beta-suppressive microenvironments, and the IL-15-embedded Tri-specific Killer Engager (TriKE).

Ingenium's business model is hybrid: clinical-stage development funded by equity (Pre-Series A of 5.7B KRW in April 2022 and Series A of 5.3B KRW in November 2023), non-dilutive grants (10B KRW KIAT CAR-NK national project in 2024, 12B KRW Scaleup Tips in December 2023), and territorial out-licensing. In 2026 it licensed gengleucel to Lipior Bio for China and Japan for up to 235 billion won ($153 million). It also monetizes through KRIBB technology transfer (1545 billion won valuation referenced) and CMO-driven manufacturing partnerships with ENCell and Matica Biolabs (CHA Biotech subsidiary) for US/global clinical supply. Go-to-market is enterprise-led: direct engagement with leading Korean university hospitals (Asan Medical Center, Samsung Medical Center, Seoul St. Mary's Hospital) for sponsored Phase 2 trials, a US subsidiary for American clinical development, an Expanded Use Program, and a dedicated patient inquiry system for international patients. The technology is protected by 11 granted patents across EU, US, and Asia.

Short descriptiontext

Ingenium Therapeutics is a South Korean clinical-stage biotech developing allogeneic Memory NK cell immunotherapy (Gengleucel) for relapsed/refractory AML and next-generation NK/CAR-NK platforms for solid tumors, serving patients via clinical trials and global licensing partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDaejeon, South Korea
HQ citystring
Daejeon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NK cell therapy, cancer immunotherapy, cell therapy platforms, acute myeloid leukemia treatment, biopharmaceutical development
Industry4 codes
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing32541
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Cell Therapy / NK Cell Immunotherapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1NK Cell Therapy Licensing
TypeLicensing Royalties
Description

Licensing of gengleucel for development and commercialization in specific territories. Example: Licensed to Lipior Bio for China and Japan for up to 235 billion won ($153 million).

koreabiomed.com
2Allogeneic Cell Therapy Products
TypeOne Time License
Description

Future revenue from off-the-shelf NK cell therapy products for cancer treatment, targeting blood cancers and solid tumors.

ingeniumcell.co.kr
3Next-generation Therapy Platforms
TypeOne Time License
Description

Revenue potential from TIS platform products (IG101, IG201) and in vivo CAR-NK (IG301) upon successful development and approval.

ingeniumcell.co.kr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Gengleucel
Description

International Non-proprietary Name (INN) proposed by WHO in 2023 for Memory NK platform developed under code IGNK001. Allogeneic memory NK cell therapy for acute myeloid leukemia.

ingeniumcell.co.kr
+6 more records
Core offering1 text field

Ingenium Therapeutics develops and commercializes allogeneic Memory NK cell-based cancer immunotherapies, with lead product Gengleucel (formerly IGNK001) targeting relapsed/refractory acute myeloid leukemia. The company leverages proprietary cytokine-induced differentiation of healthy donor PBMCs to produce Memory NK cells with enhanced cytotoxicity and 24-month cryostability for off-the-shelf use, and is expanding into solid tumors via IG301 (in vivo CAR-NK), Target Immune Stimulator (TIS) bispecific antibodies (IG101, IG201), TN13 peptide, and TriKE engager platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 37.5% Complete Remission rate in evaluable AML patients
+4 more records
Product overview1 text field

Ingenium Therapeutics is developing a comprehensive portfolio of NK cell-based cancer therapeutics centered on its Memory NK cell therapy platform, Gengleucel (International Non-proprietary Name assigned by WHO in 2023), initially targeting relapsed/refractory acute myeloid leukemia. The company is expanding through multiple technology platforms: IG301 (in vivo CAR-NK) using mRNA/LNP delivery technology for solid tumor applications; IG101 and IG201 (Target Immune Stimulator platforms) employing ROR1-targeting bispecific antibodies; plus supporting technologies including TN13 Peptide and TriKE to enhance NK cell function within the tumor microenvironment.

Product and service6 records
1Gengleucel (IGNK001)
CategoryNK Cell Immunotherapy / Cell Therapy Product
Description

Allogeneic Memory NK cell therapy for treating relapsed/refractory acute myeloid leukemia (R/R AML), manufactured from healthy donor PBMCs using proprietary cytokine differentiation without feeder cells. Off-the-shelf product potential with 24-month freeze/thaw stability and no cytokine release syndrome risk.

2IG301 (In Vivo CAR-NK)
CategoryIn Vivo Gene Therapy / Cell Therapy Platform
Description

Next-generation gene therapy platform combining mRNA-based 5th generation CAR technology with a non-lipid nanoparticle (LNP) delivery system to transiently transform NK cells into CAR-NK cells in vivo. Co-developed with Yale University and applicable to both hematologic malignancies and solid tumors.

3IG101 (Target Immune Stimulator)
CategoryBispecific Antibody / Immuno-Oncology Platform
Description

ROR1-targeting bispecific antibody platform that selectively activates immune cells within the tumor microenvironment (TME), overcoming limitations of existing ADCs and immuno-oncology drugs and aiming to improve response rates through immune modulation.

4IG201 (Target Immune Stimulator with Dual Payload)
CategoryBispecific Antibody / Immuno-Oncology Platform
Description

Next-generation TIS platform with dual payloads attacking cancer cells through multiple pathways, effective against slow-dividing cancer cells and tumors resistant to existing treatments.

5TN13 Peptide
CategoryPeptide Therapeutic / Immuno-Oncology Add-On
Description

First-in-class peptide-based p38 inhibitor that rescues NK cell function from TGF-β suppression in the tumor microenvironment. Being evaluated for synergy with Gengleucel against solid tumors including lung cancer in preclinical studies.

6Tri-specific Killer Engager (TriKE)
CategoryBispecific Engager / Cell Therapy Platform
Description

NK cell engager platform with embedded IL-15 for enhanced Memory NK cell development and activation, featuring a tailorable antibody region on a common engager backbone targeting specific tumor antigens across multiple cancer types.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-04
Description

ENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy has received FDA orphan drug designation and is planned to advance directly into Phase 2 trial following positive feedback from pre-IND meeting.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-01-20
Description

Matica Biolabs signed a CMO agreement to produce autologous memory NK cell therapies for advanced regenerative medicine. Will handle manufacturing and quality testing. Expands existing collaboration beyond immune cell therapies into broader regenerative medicine field.

3Lipior Bio
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-01
Description

Ingenium licensed gengleucel to Lipior Bio for development and commercialization in China and Japan for up to 235 billion won ($153 million), highlighting the therapy's commercial potential.

koreabiomed.com
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

Strategic MOU signed for global market entry support. Key cooperation areas include global market entry support, R&D and technology cooperation, and global investment attraction and corporate support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaborative research in progress with Yale University for CAR-NK development. Selected for 10 billion won CAR-NK national project by KIAT involving Yale University and KAIST for in vivo reprogramming CAR-NK research. Yale collaboration involves non-lipid nanoparticle delivery technology development.

6KRIBB (Korea Research Institute of Biosciences and Biotechnology)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-01
Description

Technology transfer agreement signed with KRIBB for NK cell therapy technology. Asset transfer agreement for NK anti-cancer cell therapy. KRIBB transferred technology for differentiation, mass proliferation of highly active NK cells from hematopoietic stem cells and treatment technologies for leukemia and lung cancer for 1545 billion won.

ingeniumcell.co.kr
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing allogeneic, off-the-shelf NK cell therapies for hematologic malignancies and solid tumors. Directly comparable to Ingenium's gengleucel platform given shared focus on engineered off-the-shelf NK cells for cancer.

TypeDirect peer
Description

Develops iPSC-derived NK and T-cell immunotherapies with off-the-shelf manufacturing. Competes in the same allogeneic engineered NK space as Ingenium, including programs targeting AML and solid tumors.

TypeDirect peer
Description

Cell therapy company developing placenta-derived natural killer cells (CYNK-001) and other engineered cell therapies for cancer, sharing both the NK modality and the off-the-shelf commercial positioning with Ingenium.

TypeDirect peer
Description

Develops NK cell-based therapies (haNK, t-haNK) including high-affinity NK cells for hematologic and solid tumors. Direct overlap with Ingenium's Memory NK approach in both target indications and engineered NK strategy.

TypeDirect peer
Description

Builds iPSC-derived allogeneic NK and T-cell therapies with genetic engineering, targeting hematologic malignancies and solid tumors. Directly comparable as a next-generation engineered NK platform with off-the-shelf potential.

TypeEmerging player
Description

Develops iPSC-derived allogeneic NK cell therapies for cancer. Focuses on similar indications (AML, MDS, solid tumors) to Ingenium with a parallel NK engineering approach.

7Carisma Therapeutics
TypeEmerging player
Description

Develops engineered cell therapies including CAR-macrophage and CAR-NK approaches. Shares the engineered-cell modality and oncology focus, though primary product class differs from Ingenium's NK focus.

TypeBroad incumbent
Description

Clinical-stage gene-editing company with off-the-shelf CAR-T and engineered NK cell programs (UCART, TALEN platforms). A broader incumbent in engineered allogeneic cell therapy that overlaps with Ingenium's allogeneic NK ambition.

TypeRegional player
Description

Korean biopharmaceutical company developing cell therapies including NK cell-based oncology candidates. A same-geography competitor and partner ecosystem participant compared with Ingenium.

TypeRegional player
Description

Korean biotech with cell therapy and regenerative medicine focus, parent of Matica Biolabs (Ingenium's CMO partner). Comparable regional cell therapy ecosystem player with overlapping manufacturing infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ingenium Therapeutics

Cancer Cell Therapy / NK Cell Immunotherapyingeniumcell.co.kr

Ingenium Therapeutics is a South Korean clinical-stage biotech developing allogeneic Memory NK cell immunotherapy (Gengleucel) for relapsed/refractory AML and next-generation NK/CAR-NK platforms for solid tumors, serving patients via clinical trials and global licensing partnerships.

What Ingenium Therapeutics does

Ingenium Therapeutics, Inc. is a South Korea-based clinical-stage biotechnology company founded in November 2020 as a spin-off of the Korea Research Institute of Biosciences and Biotechnology (KRIBB), commercializing NK cell-based anti-cancer immunotherapy built on roughly two decades of KRIBB research. Its core asset is Gengleucel (formerly IGNK001), an allogeneic Memory NK cell therapy manufactured from healthy donor PBMCs via a proprietary feeder-cell-free cytokine differentiation process, with enhanced activating receptors (CD94, NKG2D, NKp30, NKp44, NKp46), up to 100-fold higher IFN-gamma secretion, and 24-month freeze/thaw stability enabling off-the-shelf use. The lead indication is relapsed/refractory acute myeloid leukemia (R/R AML), where four investigator-initiated trials have enrolled 140+ patients and reported a 37.5% complete remission rate in evaluable patients; the asset received FDA Orphan Drug Designation in 2024 and positive pre-IND feedback enabling direct US Phase 2 entry. The pipeline is expanding into solid tumors via the IG301 in vivo CAR-NK platform (5th-generation mRNA CAR with non-LNP delivery, co-developed with Yale University), IG101 and IG201 ROR1-targeted Target Immune Stimulators (TIS), the TN13 peptide-based p38 inhibitor that restores NK function in TGF-beta-suppressive microenvironments, and the IL-15-embedded Tri-specific Killer Engager (TriKE).

Ingenium's business model is hybrid: clinical-stage development funded by equity (Pre-Series A of 5.7B KRW in April 2022 and Series A of 5.3B KRW in November 2023), non-dilutive grants (10B KRW KIAT CAR-NK national project in 2024, 12B KRW Scaleup Tips in December 2023), and territorial out-licensing. In 2026 it licensed gengleucel to Lipior Bio for China and Japan for up to 235 billion won ($153 million). It also monetizes through KRIBB technology transfer (1545 billion won valuation referenced) and CMO-driven manufacturing partnerships with ENCell and Matica Biolabs (CHA Biotech subsidiary) for US/global clinical supply. Go-to-market is enterprise-led: direct engagement with leading Korean university hospitals (Asan Medical Center, Samsung Medical Center, Seoul St. Mary's Hospital) for sponsored Phase 2 trials, a US subsidiary for American clinical development, an Expanded Use Program, and a dedicated patient inquiry system for international patients. The technology is protected by 11 granted patents across EU, US, and Asia.

Ingenium Therapeutics firmographics

Firmographics
Name
Ingenium Therapeutics
Legal name
Ingenium Therapeutics, Inc.
Website
https://ingeniumcell.co.kr
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Ingenium Therapeutics is a South Korean clinical-stage biotech developing allogeneic Memory NK cell immunotherapy (Gengleucel) for relapsed/refractory AML and next-generation NK/CAR-NK platforms for solid tumors, serving patients via clinical trials and global licensing partnerships.
Ownership category
akta.pro rank

Ingenium Therapeutics industry classification

Industry
Product category
Cancer Cell Therapy / NK Cell Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAD
NK Cell Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • NK cell therapy
  • Cancer immunotherapy
  • Cell therapy platforms
  • Acute myeloid leukemia treatment
  • Biopharmaceutical development

Where Ingenium Therapeutics is headquartered

Location

Headquarters

HQ city
Daejeon
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Ingenium Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. NK Cell Therapy Licensing: Licensing of gengleucel for development and commercialization in specific territories. Example: Licensed to Lipior Bio for China and Japan for up to 235 billion won ($153 million).
  2. Allogeneic Cell Therapy Products: Future revenue from off-the-shelf NK cell therapy products for cancer treatment, targeting blood cancers and solid tumors.
  3. Next-generation Therapy Platforms: Revenue potential from TIS platform products (IG101, IG201) and in vivo CAR-NK (IG301) upon successful development and approval.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Ingenium Therapeutics product offering

Product offering

Core offering

Ingenium Therapeutics develops and commercializes allogeneic Memory NK cell-based cancer immunotherapies, with lead product Gengleucel (formerly IGNK001) targeting relapsed/refractory acute myeloid leukemia. The company leverages proprietary cytokine-induced differentiation of healthy donor PBMCs to produce Memory NK cells with enhanced cytotoxicity and 24-month cryostability for off-the-shelf use, and is expanding into solid tumors via IG301 (in vivo CAR-NK), Target Immune Stimulator (TIS) bispecific antibodies (IG101, IG201), TN13 peptide, and TriKE engager platforms.

Product overview

Ingenium Therapeutics is developing a comprehensive portfolio of NK cell-based cancer therapeutics centered on its Memory NK cell therapy platform, Gengleucel (International Non-proprietary Name assigned by WHO in 2023), initially targeting relapsed/refractory acute myeloid leukemia. The company is expanding through multiple technology platforms: IG301 (in vivo CAR-NK) using mRNA/LNP delivery technology for solid tumor applications; IG101 and IG201 (Target Immune Stimulator platforms) employing ROR1-targeting bispecific antibodies; plus supporting technologies including TN13 Peptide and TriKE to enhance NK cell function within the tumor microenvironment.

Differentiator

Problem solved

Functional benefit

Brands

  • Gengleucel: International Non-proprietary Name (INN) proposed by WHO in 2023 for Memory NK platform developed under code IGNK001. Allogeneic memory NK cell therapy for acute myeloid leukemia.
  • IGNK001
  • TN13 Peptide
  • TriKE
  • IG301
  • IG101 (TIS)
  • IG201 (TIS)

Products and services

  • Gengleucel (IGNK001) Allogeneic Memory NK cell therapy for treating relapsed/refractory acute myeloid leukemia (R/R AML), manufactured from healthy donor PBMCs using proprietary cytokine differentiation without feeder cells. Off-the-shelf product potential with 24-month freeze/thaw stability and no cytokine release syndrome risk.
  • IG301 (In Vivo CAR-NK) Next-generation gene therapy platform combining mRNA-based 5th generation CAR technology with a non-lipid nanoparticle (LNP) delivery system to transiently transform NK cells into CAR-NK cells in vivo. Co-developed with Yale University and applicable to both hematologic malignancies and solid tumors.
  • IG101 (Target Immune Stimulator) ROR1-targeting bispecific antibody platform that selectively activates immune cells within the tumor microenvironment (TME), overcoming limitations of existing ADCs and immuno-oncology drugs and aiming to improve response rates through immune modulation.
  • IG201 (Target Immune Stimulator with Dual Payload) Next-generation TIS platform with dual payloads attacking cancer cells through multiple pathways, effective against slow-dividing cancer cells and tumors resistant to existing treatments.
  • TN13 Peptide First-in-class peptide-based p38 inhibitor that rescues NK cell function from TGF-β suppression in the tumor microenvironment. Being evaluated for synergy with Gengleucel against solid tumors including lung cancer in preclinical studies.
  • Tri-specific Killer Engager (TriKE) NK cell engager platform with embedded IL-15 for enhanced Memory NK cell development and activation, featuring a tailorable antibody region on a common engager backbone targeting specific tumor antigens across multiple cancer types.

Quantifiable outcome

  • 37.5% Complete Remission rate in evaluable AML patients
  • +4 more outcomes

Companies that use Ingenium Therapeutics

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Ingenium Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Ingenium Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and strategic.

  • ENCellcoreTechnology or Integration · 4 June 2026ENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy has received FDA orphan drug designation and is planned to advance directly into Phase 2 trial following positive feedback from pre-IND meeting.
  • Matica Biolabs (CHA Biotech subsidiary)strategicTechnology or Integration · 20 January 2026Matica Biolabs signed a CMO agreement to produce autologous memory NK cell therapies for advanced regenerative medicine. Will handle manufacturing and quality testing. Expands existing collaboration beyond immune cell therapies into broader regenerative medicine field.
  • Lipior BiocoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Ingenium licensed gengleucel to Lipior Bio for development and commercialization in China and Japan for up to 235 billion won ($153 million), highlighting the therapy's commercial potential.
  • KBIOHealth (Osong Advanced Medical-Health Industry Development Foundation)strategicStrategic or Co-development Partner · 1 April 2025Strategic MOU signed for global market entry support. Key cooperation areas include global market entry support, R&D and technology cooperation, and global investment attraction and corporate support.
  • Yale UniversitycoreStrategic or Co-development Partner · 1 January 2024Collaborative research in progress with Yale University for CAR-NK development. Selected for 10 billion won CAR-NK national project by KIAT involving Yale University and KAIST for in vivo reprogramming CAR-NK research. Yale collaboration involves non-lipid nanoparticle delivery technology development.
  • KRIBB (Korea Research Institute of Biosciences and Biotechnology)coreTechnology or Integration · 1 January 2021Technology transfer agreement signed with KRIBB for NK cell therapy technology. Asset transfer agreement for NK anti-cancer cell therapy. KRIBB transferred technology for differentiation, mass proliferation of highly active NK cells from hematopoietic stem cells and treatment technologies for leukemia and lung cancer for 1545 billion won.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Ingenium Therapeutics competitors and assessment

Company assessment

Direct peers

  • Nkarta Therapeutics: Clinical-stage biotech developing allogeneic, off-the-shelf NK cell therapies for hematologic malignancies and solid tumors. Directly comparable to Ingenium's gengleucel platform given shared focus on engineered off-the-shelf NK cells for cancer.
  • Fate Therapeutics: Develops iPSC-derived NK and T-cell immunotherapies with off-the-shelf manufacturing. Competes in the same allogeneic engineered NK space as Ingenium, including programs targeting AML and solid tumors.
  • Celularity: Cell therapy company developing placenta-derived natural killer cells (CYNK-001) and other engineered cell therapies for cancer, sharing both the NK modality and the off-the-shelf commercial positioning with Ingenium.
  • ImmunityBio: Develops NK cell-based therapies (haNK, t-haNK) including high-affinity NK cells for hematologic and solid tumors. Direct overlap with Ingenium's Memory NK approach in both target indications and engineered NK strategy.
  • Century Therapeutics: Builds iPSC-derived allogeneic NK and T-cell therapies with genetic engineering, targeting hematologic malignancies and solid tumors. Directly comparable as a next-generation engineered NK platform with off-the-shelf potential.

Emerging players

  • Shoreline Biosciences: Develops iPSC-derived allogeneic NK cell therapies for cancer. Focuses on similar indications (AML, MDS, solid tumors) to Ingenium with a parallel NK engineering approach.
  • Carisma Therapeutics: Develops engineered cell therapies including CAR-macrophage and CAR-NK approaches. Shares the engineered-cell modality and oncology focus, though primary product class differs from Ingenium's NK focus.

Broad incumbents

  • Cellectis: Clinical-stage gene-editing company with off-the-shelf CAR-T and engineered NK cell programs (UCART, TALEN platforms). A broader incumbent in engineered allogeneic cell therapy that overlaps with Ingenium's allogeneic NK ambition.

Regional players

  • GC Biopharma (formerly Green Cross): Korean biopharmaceutical company developing cell therapies including NK cell-based oncology candidates. A same-geography competitor and partner ecosystem participant compared with Ingenium.
  • CHA Biotech: Korean biotech with cell therapy and regenerative medicine focus, parent of Matica Biolabs (Ingenium's CMO partner). Comparable regional cell therapy ecosystem player with overlapping manufacturing infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ingenium Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ingenium Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Ingenium Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ingenium Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ingenium Therapeutics

What does Ingenium Therapeutics do?

Ingenium Therapeutics develops and commercializes allogeneic Memory NK cell-based cancer immunotherapies, with lead product Gengleucel (formerly IGNK001) targeting relapsed/refractory acute myeloid leukemia. The company leverages proprietary cytokine-induced differentiation of healthy donor PBMCs to produce Memory NK cells with enhanced cytotoxicity and 24-month cryostability for off-the-shelf use, and is expanding into solid tumors via IG301 (in vivo CAR-NK), Target Immune Stimulator (TIS) bispecific antibodies (IG101, IG201), TN13 peptide, and TriKE engager platforms.

Is Ingenium Therapeutics a public or private company?

Ingenium Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ingenium Therapeutics founded?

Ingenium Therapeutics was founded in 2020. It employs 11 to 50 people.

Where is Ingenium Therapeutics based?

Ingenium Therapeutics is headquartered in Daejeon, South Korea, in the Asia region.

How does Ingenium Therapeutics make money?

Three revenue lines are on record. NK Cell Therapy Licensing is the primary driver. The others are allogeneic Cell Therapy Products and next-generation Therapy Platforms.

Who are Ingenium Therapeutics's main competitors?

Direct peers on record are Nkarta Therapeutics, Fate Therapeutics, Celularity, ImmunityBio and Century Therapeutics. Emerging players are Shoreline Biosciences and Carisma Therapeutics. Cellectis is listed as a broad incumbent. Regional players are GC Biopharma (formerly Green Cross) and CHA Biotech.

Does Ingenium Therapeutics have an API?

No public API is recorded for Ingenium Therapeutics.

What industry is Ingenium Therapeutics in?

Ingenium Therapeutics's product category is Cancer Cell Therapy / NK Cell Immunotherapy. Its primary akta.pro industry code is HLAAABAD, NK Cell Therapies, with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
KBRMatica Biolabs signs CMO deal with Ingenium for autologous memory NK cell therapyMatica Biolabs, a subsidiary of CHA Biotech, signed a contract manufacturing organization agreement with Ingenium Therapeutics to produce autologous memory NK cell therapies for advanced regenerative medicine. Matica Biolabs will handle manufacturing and quality testing, while Ingenium Therapeutics plans to administer the therapies to cancer recurrence patients in Hong Kong and conduct a phase 2 clinical trial for acute myeloid leukemia at three hospitals in Korea. The agreement expands their existing collaboration beyond immune cell therapies into the broader field of advanced regenerative medicine, with the technology having demonstrated safety and efficacy through four clinical trials over 20 years.PR NewswireIngenium Therapeutics Receives FDA Feedback Enabling Direct Phase 2 Trial for Gengleucel in MRD+ AMLIngenium Therapeutics received positive regulatory feedback from the U.S. FDA following a Pre-IND meeting, enabling the company to initiate a direct Phase 2 trial for Gengleucel in MRD+ acute myeloid leukemia without a preceding Phase 1 study. The FDA's decision was based on robust clinical data from over 140 patients enrolled in investigator-initiated trials previously conducted in South Korea. The planned multicenter Phase 2 trial is expected to begin in early 2026 at leading U.S. cancer centers, with product manufacturing being transferred to a Texas-based facility.PR NewswireIngenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDAIngenium Therapeutics announced that its investigational NK cell therapy, IGNK001 (Gengluecel), received Orphan Drug Designation from the U.S. Food and Drug Administration for treating acute myeloid leukemia. This designation provides development incentives such as tax credits and market exclusivity potential, supporting the company's plan to initiate U.S. clinical trials targeting 80 subjects by December 2027.PlatumBiotech company 'Ingenium Therapeutics' secures 5.3 billion won in Series A funding.Ingenium Therapeutics has secured 5.3 billion won in Series A funding to support the development of next-generation NK cell therapies and related immuno-oncology drugs. This new funding raises the total investment received by the company to 14 billion won, and it will facilitate the acceleration of Phase 2 clinical trials and overseas expansion. The investment underscores confidence in Ingenium's technology and clinical capabilities, which are aimed at enhancing cancer treatment.GetnewsIngenium Therapeutics secures 5.3 billion won in Series A funding.. funds for research and business development securedIngenium Therapeutics has secured 5.3 billion won in Series A funding to support its research and business development. The funds will be used for the commercialization clinical trial of Gengleucel for patients with refractory acute myeloid leukemia, which will take place at major university hospitals in Korea. The company's long-term aim is to advance anti-cancer immune cell therapy to improve cancer treatment paradigms.WowtvIngenium Therapeutics develops NK cell therapeutics, raising 5.7 billion won in investment.Ingenium Therapeutics secured a 5.7 billion won pre-Series A investment from venture capital firms Capstone Partners, K-Ground, Kairos Investment, Maple, and Laplace to fund its development of NK cell therapeutics for anti-cancer treatments. The company plans to apply for clinical phases 1 and 2 trials for refractory acute myeloid leukemia with the Ministry of Food and Drug Safety by the end of the month. These trials will be conducted at Seoul Asan Hospital, Samsung Medical Center, and Seoul St. Mary's Hospital.